Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

131.89 -1.15 (-0.86%)
Official Closing Price Updated: 4:10 PM EDT, May 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,589,119
Open 131.94
Bid (Size) 131.65 (1)
Ask (Size) 131.99 (1)
Prev. Close 133.04
Today's Range 130.85 - 132.09
52wk Range 75.56 - 138.28
Shares Outstanding N/A
Dividend Yield 1.34%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
EXCLUSIVE: GameStop, AMC Buzz 'May Prove To Be Short-Lived,' CEO Of Company Behind MEME ETF Tells Benzinga
The company behind the MEME ETF shares what it would take to bring the meme stock fund back to the market. 
Via Benzinga
Topics ETFs
Pharma Stocks Outlook: Where Are 2024’s Top Performers Headed Next?
Investors want to know where 2024's top-performing pharma stocks are headed in the second half of the year for good reason. 
Via InvestorPlace

Performance

YTD
+29.16%
+29.16%
1 Month
+6.84%
+6.84%
3 Month
+8.33%
+8.33%
6 Month
+32.51%
+32.51%
1 Year
+57.86%
+57.86%

More News

Read More
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Smart Money Is Betting Big In NVO Options
Via Benzinga
Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 10 Years
Via Benzinga
Should Quality Investors Include NYSE:NVO in Their Portfolio?
Via Chartmill
Spotlight on Novo Nordisk: Analyzing the Surge in Options Activity
Via Benzinga
Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries
Via News Direct
Meet the GLP-1 Drug That Could Be the Biggest Concern for Eli Lilly and Novo Nordisk
Via The Motley Fool
7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade
Via InvestorPlace
Topics Intellectual Property
Exposures Intellectual Property
No Wegovy Shortage in Denmark Amid High Demand, Novo Nordisk Confirms
Via Benzinga
If You'd Invested $1,000 in Novo Nordisk Stock 5 Years Ago, Here's How Much You'd Have Today
Via The Motley Fool
Eli Lilly Strikes Deal To Combat Counterfeit Diabetes And Weight Loss Drugs Mounjaro And Zepbound
Via Benzinga
Novo Nordisk Bets Up to $600 Million on Ozempic 2.0. Here's Why the Stock Is a Buy.
Via The Motley Fool
2 Top Pharma Stocks That Just Keep Getting Better and Better
Via The Motley Fool
Novo Nordisk's Wegovy Delivers: Long-Term Study Shows Sustained Weight Loss As Drugmaker Tries To Woo Insurers And Governments
Via Benzinga
Novo Nordisk's Hemophilia Candidate Can Prevent Bleeding Episodes Effectively, Regardless Of Dosing Frequency
Via Benzinga
How Viking Therapeutics Stock Could 30x
Via The Motley Fool
The Must-Watch List: 3 Stocks to Snap Up as Soon as They Hit Bargain Territory
Via InvestorPlace
Billionaire Jim Simons Owns These 2 Healthcare Stocks: Should You?
Via The Motley Fool
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.
Via The Motley Fool
7 Stocks That Ordinary Investors Can’t Get Enough Of Right Now
Via InvestorPlace
Can Weight Loss Companies Fuel Gains In Your Stock Portfolio?
Via Talk Markets
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.